By contrast, unlike Erastin, Compound 53 did not significantly increase cellular ROS levels, consistent with a previous report that NFS1 knockdown via siRNA did not affect ROS levels in lung cancer cells [16]. This evidence concerns the gene NFS1 and lung carcinoma.